ClinicalTrials.gg
CompletedNCT00074854Updated Nov 9, 2006

A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

A Phase 1/2 interventional study of CP-547,632 in Lung Neoplasms, sponsored by Pfizer. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-11-09.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Lung Neoplasms by Pfizer — 6 open to participants now, 9 under way, 3 of them phase 3. Lung Neoplasms · Pfizer.

Enrollment
15th of 40
87 · median 46
Started
2002
the only one that year
Phase 1/2
3 of 48
none open now
Registered
8th of 48
by date

Among the 48 studies in Lung Neoplasms by Pfizer, this one is the 15th largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2002, is one of 3 in phase 1/2, and was the 8th registered.

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

6 of the 48 studies in Lung Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Lung Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage non-small cell lung cancer.

03

Conditions studied

  • Lung Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed stage IIIB (inicluding those with pleural effusion), IV or recurrent non-small cell lung cancer (nsclc).
  • Bidimensionally >2cm x 1 cm by conventional CT Scan or >1 cm x 1cm by spiral CT Scan.

Exclusion criteria

Exclusion Criteria:

  • No tumors in close proximity to major veins or arteries.
  • No sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease.
  • No evidence or history .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Statistical estimates used on the Stage 1 data indicated low likely-hood of a positive outcome if the study continued to Stage 2. This provided the basis for discontinuation of the trial.

Secondary outcomes

  1. Given the outcome of the primary objective, analysis of secondary objectives were not formalized.

07

Study locations

20 sites
  • Pfizer Investigational Site
    Greenbrae, California 94904, United States
  • Pfizer Investigational Site
    San Mateo, California 94402, United States
  • Pfizer Investigational Site
    San Pablo, California 94806, United States
  • Pfizer Investigational Site
    Tampa, Florida 33612-9497, United States
  • Pfizer Investigational Site
    Covington, Louisiana 70433, United States
  • Pfizer Investigational Site
    Metairie, Louisiana 70002, United States
  • Pfizer Investigational Site
    Metairie, Louisiana 70006, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70115, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Stony Brook, New York 11794, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • Pfizer Investigational Site
    Gallatin, Tennessee 37066, United States
  • Pfizer Investigational Site
    Hermitage, Tennessee 37076, United States
  • Pfizer Investigational Site
    Lebanon, Tennessee 37087, United States
  • Pfizer Investigational Site
    Murfreesboro, Tennessee 37130, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37205, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37207, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37211, United States
  • Pfizer Investigational Site
    Smyrna, Tennessee 37167, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2003
First posted
Dec 24, 2003
Start
May 2002
Completion
Mar 2005
Last update
Nov 9, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 9, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00074854
Lead sponsor
Pfizer
First posted
Dec 24, 2003
Start date
May 2002
Completion
Mar 2005
Last update
Nov 9, 2006

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cp-547632

Start the discussion